Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality

Journal Article · · Journal of Medicinal Chemistry
 [1];  [2];  [2];  [1];  [1];  [1];  [1];  [2];  [2];  [2];  [1];  [2];  [1];  [3];  [3];  [2];  [2];  [2];  [2];  [1] more »;  [1];  [2];  [1] « less
  1. Pfizer Worldwide Research and Development, Cambridge, MA (United States)
  2. Pfizer Worldwide Research and Development, Groton, CT (United States)
  3. The Scripps Research Inst., La Jolla, CA (United States)
+ Show Author Affiliations
A growing subset of $$β$$-secretase (BACE1) inhibitors for the treatment of Alzheimer’s disease (AD) utilizes an anilide chemotype that engages a key residue (Gly230) in the BACE1 binding site. Although the anilide moiety affords excellent potency, it simultaneously introduces a third hydrogen bond donor that limits brain availability and provides a potential metabolic site leading to the formation of an aniline, a structural motif of prospective safety concern. We report herein an alternative aminomethyl linker that delivers similar potency and improved brain penetration relative to the amide moiety. Optimization of this series identified analogues with an excellent balance of ADME properties and potency; however, potential drug–drug interactions (DDI) were predicted based on CYP 2D6 affinities. Generation and analysis of key BACE1 and CYP 2D6 crystal structures identified strategies to obviate the DDI liability, leading to compound 16, which exhibits robust in vivo efficacy as a BACE1 inhibitor.
Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS); SLAC National Accelerator Laboratory, Menlo Park, CA (United States). Stanford Synchrotron Radiation Lightsource (SSRL)
Sponsoring Organization:
Industrial Macromolecular Crystallography Association; National Center for Research Resources, Biomedical Technology Program; National Institute of General Medical Sciences (NIGMS); National Institutes of Health (NIH); USDOE Office of Science (SC), Basic Energy Sciences (BES) (SC-22); USDOE Office of Science (SC), Biological and Environmental Research (BER) (SC-23)
Grant/Contract Number:
AC02-06CH11357; AC02-76SF00515
OSTI ID:
1506536
Journal Information:
Journal of Medicinal Chemistry, Journal Name: Journal of Medicinal Chemistry Journal Issue: 1 Vol. 60; ISSN 0022-2623
Publisher:
American Chemical Society (ACS)Copyright Statement
Country of Publication:
United States
Language:
ENGLISH

References (52)

BACE1 as a Therapeutic Target in Alzheimer’s Disease: Rationale and Current Status journal July 2013
Amyloid deposition as the central event in the aetiology of Alzheimer's disease journal January 1991
The evolution of amidine-based brain penetrant BACE1 inhibitors journal May 2014
Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective journal February 2005
A novel approach to identifying β-secretase inhibitors: Bis-statine peptide mimetics discovered using structure and spot synthesis journal July 2006
1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads journal October 2015
Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain Aβ Reduction in Rodents journal January 2016
Medicinal Chemistry of hERG Optimizations:  Highlights and Hang-Ups journal August 2006
β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer’s Disease journal May 2013
Discovery of a Series of Efficient, Centrally Efficacious BACE1 Inhibitors through Structure-Based Drug Design journal February 2015
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline journal July 2012
Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice journal February 2016
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs: Molecular genetics of CYP2D6 journal January 2002
BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells journal June 2013
Characterization of Potassium Channel Modulators with QPatch ™ Automated Patch-Clamp Technology: System Characteristics and Performance journal October 2003
XDS journal January 2010
Data processing and analysis with the autoPROC toolbox journal March 2011
The CCP4 suite programs for protein crystallography journal September 1994
Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS journal September 2014
Cerebrospinal Fluid Amyloid-β (Aβ) as an Effect Biomarker for Brain Aβ Lowering Verified by Quantitative Preclinical Analyses journal May 2012
Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process journal April 2010
Robust Central Reduction of Amyloid-  in Humans with an Orally Available, Non-Peptidic  -Secretase Inhibitor journal November 2011
The  -Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential journal October 2009
PHENIX: a comprehensive Python-based system for macromolecular structure solution. text January 2010
Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery journal January 2002
Measurement of Dissociation Constants (pKa Values) of Organic Compounds by Multiplexed Capillary Electrophoresis Using Aqueous and Cosolvent Buffers**Advanced Analytical Technologies, Inc. (Formerly CombiSep), 2711 South Loop Drive, Suite 4200, Ames, IA 50010. journal July 2008
BACE and γ-Secretase Characterization and Their Sorting as Therapeutic Targets to Reduce Amyloidogenesis journal September 2009
A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel journal April 1995
Amyloid deposition as the central event in the aetiology of Alzheimer's disease journal January 1991
A quantitative assessment of hERG liability as a function of lipophilicity journal March 2007
BACE1 inhibitors: A head group scan on a series of amides journal July 2013
Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors journal March 2015
Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties journal March 2010
Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States journal September 2011
hERG potassium channels and cardiac arrhythmia journal March 2006
Drug-Induced Prolongation of the QT Interval journal March 2004
On the treatment of negative intensity observations journal July 1978
Coot model-building tools for molecular graphics journal November 2004
XDS journal January 2010
PHENIX: a comprehensive Python-based system for macromolecular structure solution journal January 2010
Data processing and analysis with the autoPROC toolbox journal March 2011
The CCP4 suite programs for protein crystallography journal September 1994
Refinement of Macromolecular Structures by the Maximum-Likelihood Method journal May 1997
The Alzheimer's disease Beta-secretase enzyme, BACE1 journal January 2007
Robust Central Reduction of Amyloid-  in Humans with an Orally Available, Non-Peptidic  -Secretase Inhibitor journal November 2011
The  -Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential journal October 2009
Pharmacogenomics of CYP2D6: Molecular Genetics, Interethnic Differences and Clinical Importance journal January 2012
Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors journal January 1997
BACE1 as a Potential Biomarker for Alzheimer's Disease journal April 2011
The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer’s Disease and Beyond journal January 2012
Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States journal September 2011
Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties journal June 2010

Cited By (4)

Biotransformation, Using Recombinant CYP450-Expressing Baker’s Yeast Cells, Identifies a Novel CYP2D6.10A122V Variant Which Is a Superior Metabolizer of Codeine to Morphine Than the Wild-Type Enzyme journal August 2018
Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment journal May 2018
Quantum Mechanics/Molecular Mechanics Studies on the Relative Reactivities of Compound I and II in Cytochrome P450 Enzymes journal July 2018
Out-compute drug side effects: Focus on cytochrome P450 2D6 modeling journal May 2018

Similar Records

Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors
Journal Article · Tue Mar 17 00:00:00 UTC 2015 · Journal of Medicinal Chemistry · OSTI ID:1183594
How Informative Are Drug‐Drug Interactions of Gene‐Drug Interactions?
Journal Article · Tue Apr 26 00:00:00 UTC 2016 · Journal of Clinical Pharmacology · OSTI ID:1400958
Regulation of gamma-Secretase in Alzheimer's Disease
Journal Article · Wed Feb 07 04:00:00 UTC 2007 · Biochemistry · OSTI ID:918642

Related Subjects

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY
Amines
Inhibition
Inhibitors
Selectivity
Substituents